Ezogabine for the adjunctive treatment of partial onset seizures in adults with epilepsy

Research output: Contribution to journalReview article

Abstract

Partial seizures are frequently resistant to pharmacologic treatment. There are a plethora of medications currently approved for use in partial epilepsy. However, despite the large number of medications available, seizure control often remains elusive. A new medication with a unique mechanism of action has recently been approved for the adjunctive treatment of partial seizures in adults. Ezogabine (retigabine) exerts its actions at the level of voltage-gated potassium channels. In clinical trials it has demonstrated efficacy similar to that of other agents approved for resistant partial epilepsy. Adverse events tend to be central nervous system related. However, significant urinary retention has been noted in some persons exposed to the drug. A Risk Evaluation and Mitigation Strategy is being implemented to minimize urinary adverse events. Ezogabine represents an important addition to the partial epilepsy medication arsenal.

Original languageEnglish
Pages (from-to)441-448
Number of pages8
JournalClinical Medicine Insights: Therapeutics
Volume3
DOIs
StatePublished - 2011

Fingerprint

Partial Epilepsy
Epilepsy
Seizures
Voltage-Gated Potassium Channels
Urinary Retention
Central Nervous System
Clinical Trials
Pharmaceutical Preparations
ezogabine

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pharmaceutical Science
  • Pharmacology

Cite this

@article{a079b3b6cba04dc6b3e4d9896e160fbb,
title = "Ezogabine for the adjunctive treatment of partial onset seizures in adults with epilepsy",
abstract = "Partial seizures are frequently resistant to pharmacologic treatment. There are a plethora of medications currently approved for use in partial epilepsy. However, despite the large number of medications available, seizure control often remains elusive. A new medication with a unique mechanism of action has recently been approved for the adjunctive treatment of partial seizures in adults. Ezogabine (retigabine) exerts its actions at the level of voltage-gated potassium channels. In clinical trials it has demonstrated efficacy similar to that of other agents approved for resistant partial epilepsy. Adverse events tend to be central nervous system related. However, significant urinary retention has been noted in some persons exposed to the drug. A Risk Evaluation and Mitigation Strategy is being implemented to minimize urinary adverse events. Ezogabine represents an important addition to the partial epilepsy medication arsenal.",
author = "Faulkner, {Michele A.}",
year = "2011",
doi = "10.4137/CMT.S7241",
language = "English",
volume = "3",
pages = "441--448",
journal = "Clinical Medicine Insights: Therapeutics",
issn = "1179-559X",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Ezogabine for the adjunctive treatment of partial onset seizures in adults with epilepsy

AU - Faulkner, Michele A.

PY - 2011

Y1 - 2011

N2 - Partial seizures are frequently resistant to pharmacologic treatment. There are a plethora of medications currently approved for use in partial epilepsy. However, despite the large number of medications available, seizure control often remains elusive. A new medication with a unique mechanism of action has recently been approved for the adjunctive treatment of partial seizures in adults. Ezogabine (retigabine) exerts its actions at the level of voltage-gated potassium channels. In clinical trials it has demonstrated efficacy similar to that of other agents approved for resistant partial epilepsy. Adverse events tend to be central nervous system related. However, significant urinary retention has been noted in some persons exposed to the drug. A Risk Evaluation and Mitigation Strategy is being implemented to minimize urinary adverse events. Ezogabine represents an important addition to the partial epilepsy medication arsenal.

AB - Partial seizures are frequently resistant to pharmacologic treatment. There are a plethora of medications currently approved for use in partial epilepsy. However, despite the large number of medications available, seizure control often remains elusive. A new medication with a unique mechanism of action has recently been approved for the adjunctive treatment of partial seizures in adults. Ezogabine (retigabine) exerts its actions at the level of voltage-gated potassium channels. In clinical trials it has demonstrated efficacy similar to that of other agents approved for resistant partial epilepsy. Adverse events tend to be central nervous system related. However, significant urinary retention has been noted in some persons exposed to the drug. A Risk Evaluation and Mitigation Strategy is being implemented to minimize urinary adverse events. Ezogabine represents an important addition to the partial epilepsy medication arsenal.

UR - http://www.scopus.com/inward/record.url?scp=80555146747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80555146747&partnerID=8YFLogxK

U2 - 10.4137/CMT.S7241

DO - 10.4137/CMT.S7241

M3 - Review article

AN - SCOPUS:80555146747

VL - 3

SP - 441

EP - 448

JO - Clinical Medicine Insights: Therapeutics

JF - Clinical Medicine Insights: Therapeutics

SN - 1179-559X

ER -